BR112015021719A2 - inibidores de quinase de tirosina de bruton - Google Patents

inibidores de quinase de tirosina de bruton

Info

Publication number
BR112015021719A2
BR112015021719A2 BR112015021719A BR112015021719A BR112015021719A2 BR 112015021719 A2 BR112015021719 A2 BR 112015021719A2 BR 112015021719 A BR112015021719 A BR 112015021719A BR 112015021719 A BR112015021719 A BR 112015021719A BR 112015021719 A2 BR112015021719 A2 BR 112015021719A2
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
kinase inhibitors
compounds
bruton tyrosine
diseases associated
Prior art date
Application number
BR112015021719A
Other languages
English (en)
Other versions
BR112015021719A8 (pt
Inventor
E Brotherton-Pleiss Christine
Javier Lopez-Tapia Francisco
K Kondru Rama
Lou Yan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015021719A2 publication Critical patent/BR112015021719A2/pt
Publication of BR112015021719A8 publication Critical patent/BR112015021719A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1/1 resumo inibidores de quinase de tirosina de bruton esse pedido revela compostos de acordo com fórmula genérica i: ohnonhnnxoyr i (i) em que todas as variáveis são definidas conforme descrito aqui, as quais inibem btk. os compostos revelados aqui são úteis para modular a atividade de btk e tratar doenças associadas com atividade excessiva de btk. os compostos são ainda úteis para tratar doenças inflamatórias e autoimunes associadas com proliferação aberrante de célula b, tal como artrite reumatóide. são também reveladas composições que contêm compostos da fórmula i e pelo menos um veículo, diluente ou excipiente.
BR112015021719A 2013-03-05 2014-03-03 inibidores de tirosina quinase de bruton BR112015021719A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772948P 2013-03-05 2013-03-05
PCT/EP2014/054014 WO2014135470A1 (en) 2013-03-05 2014-03-03 Inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
BR112015021719A2 true BR112015021719A2 (pt) 2017-07-18
BR112015021719A8 BR112015021719A8 (pt) 2019-11-19

Family

ID=50190452

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021719A BR112015021719A8 (pt) 2013-03-05 2014-03-03 inibidores de tirosina quinase de bruton

Country Status (11)

Country Link
US (1) US9556147B2 (pt)
EP (1) EP2964627B1 (pt)
JP (1) JP6089124B2 (pt)
KR (1) KR101737724B1 (pt)
CN (1) CN105051028B (pt)
BR (1) BR112015021719A8 (pt)
CA (1) CA2902038C (pt)
HK (1) HK1214257A1 (pt)
MX (1) MX2015010820A (pt)
RU (1) RU2618529C2 (pt)
WO (1) WO2014135470A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014076104A1 (en) * 2012-11-16 2014-05-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2242749T3 (da) 2008-02-05 2013-06-17 Hoffmann La Roche Nye pyridinoner og pyridazinoner
EP2297142B1 (en) * 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones
KR101320763B1 (ko) 2008-07-02 2013-10-21 에프. 호프만-라 로슈 아게 키나아제 억제제로서의 신규 페닐피라지논
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2841801A1 (en) 2011-08-17 2013-02-21 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
WO2014135470A1 (en) 2014-09-12
CN105051028B (zh) 2017-06-09
KR101737724B1 (ko) 2017-05-29
KR20150123318A (ko) 2015-11-03
MX2015010820A (es) 2015-11-30
US20160002206A1 (en) 2016-01-07
EP2964627B1 (en) 2017-03-01
RU2618529C2 (ru) 2017-05-04
US9556147B2 (en) 2017-01-31
JP6089124B2 (ja) 2017-03-01
BR112015021719A8 (pt) 2019-11-19
HK1214257A1 (zh) 2016-07-22
EP2964627A1 (en) 2016-01-13
CA2902038C (en) 2017-05-16
JP2016510049A (ja) 2016-04-04
CA2902038A1 (en) 2014-09-12
CN105051028A (zh) 2015-11-11
RU2015141357A (ru) 2017-04-10

Similar Documents

Publication Publication Date Title
BR112015010693A2 (pt) inibidores de tirosina quinase de bruton
BR112014013582A2 (pt) inibidores de quinase de tirosina de bruton
BR112014003582A2 (pt) inibidores da tirosina quinase de bruton
BR112015007513A2 (pt) inibidores de tirosina quinase de bruton
BR112015021806A2 (pt) inibidores de tirosina cinase de bruton
BR112013003114A2 (pt) inibidores de tirosina quinase de bruton
MX345170B (es) Inhibidores de la tirosina-cinasa de bruton.
BR112015021677A2 (pt) inibidores de tirosina quinase de bruton
BR112018012112A2 (pt) heteroaril-hidroxipirimidinonas como agonistas do receptor apj
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
BR112018003595A2 (pt) análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112015013762A2 (pt) derivados de tiazol como inibidores de tirosina cinase de bruton
BR112012024117A2 (pt) inibidores de pirrolopirazina quinase
BR112015032595A8 (pt) inibidores de ido
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
BR112015032664A2 (pt) composições
BR112017023780A2 (pt) sulfonas tricíclicas como moduladores de rorgama
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112018077075A2 (pt) heterociclos de biarilmetila
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
MX2019013419A (es) Compuestos plaguicidas biciclicos.
BR112017009629A2 (pt) triazolo [4,5-d] pirimidinas como agonistas do receptor canabinoide 2

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2556 DE 31/12/2019.